Pliant Therapeutics to Participate in Upcoming Investor Events
2024年8月28日 - 9:00PM
Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage
biotechnology company and leader in the discovery and development
of novel therapeutics for the treatment of fibrotic diseases, today
announced participation in the following September investor events.
- 2024 Wells Fargo Healthcare
Conference Keith Cummings, M.D., Pliant’s Chief Financial
Officer, and Éric Lefebvre, M.D., Pliant’s Chief Medical Officer,
will participate in a fireside chat on Wednesday, September 4,
2024, at 1:30 p.m. Eastern Time.
- H.C. Wainwright
26th Annual Global Investment
Conference Keith Cummings, M.D. and Éric Lefebvre, M.D.,
will participate in a fireside chat on Wednesday, September 11,
2024, at 10:30 a.m. Eastern Time.
- 2024 Cantor Global
Healthcare Conference Bernard Coulie, M.D., Ph.D.,
Pliant’s President and Chief Executive Officer, Keith Cummings,
M.D., and Éric Lefebvre, M.D., will participate in a fireside chat
on Tuesday, September 17, 2024, at 10:20 a.m. Eastern Time.
- Stifel 2024 Virtual
Immunology and Inflammation Summit Bernard Coulie, M.D.,
Ph.D., and Keith Cummings, M.D. will participate in a fireside chat
on Wednesday, September 18, 2024, at 11:00 a.m. Eastern Time.
Interested parties may access the live webcasts of these
fireside chats by visiting the Investor Relations’ Events
& Presentation page of Pliant’s website. The webcast
replays will be archived on the Pliant website for 30 days
following the conclusion of the events.
About Pliant Therapeutics, Inc.
Pliant Therapeutics is a late-stage biopharmaceutical company
and leader in the discovery and development of novel therapeutics
for the treatment of fibrotic diseases. Pliant's lead product
candidate, bexotegrast (PLN-74809), is an oral, small molecule,
dual selective inhibitor of αvß6 and αvß1 integrins that is in
development in the lead indications for the treatment of idiopathic
pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or
PSC. Bexotegrast has received Fast Track Designation and Orphan
Drug Designation from the U.S. Food and Drug Administration (FDA)
in IPF and PSC and Orphan Drug Designation from the European
Medicines Agency in IPF and PSC. Pliant has initiated BEACON-IPF,
an adaptive Phase 2b/3 trial of bexotegrast in IPF. Pliant is
conducting a Phase 1 study for its third clinical program,
PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and
αvß1 integrins, that is being developed for the treatment of solid
tumors. In addition, Pliant has received regulatory clearance for
the conduct of a Phase 1 study of PLN-101325, a monoclonal antibody
agonist of integrin α7β1 targeting muscular dystrophies.
For additional information, please visit: www.PliantRx.com.
Follow us on social media: X, LinkedIn, and
Facebook.
Investor and Media Contact:
Christopher KeenanVice President, Investor Relations and
Corporate CommunicationsPliant Therapeutics,
Inc.ir@pliantrx.com
Pliant Therapeutics (NASDAQ:PLRX)
過去 株価チャート
から 10 2024 まで 11 2024
Pliant Therapeutics (NASDAQ:PLRX)
過去 株価チャート
から 11 2023 まで 11 2024